林奇综合征中腺瘤及进展期腺瘤的基因特异性检出率
这项多中心研究分析了1072例无结直肠癌史的林奇综合征携带者接受监测性结肠镜检查的数据,比较MLH1/MSH2与MSH6/PMS2突变携带者间腺瘤及进展期腺瘤(AA)检出率。结果显示总体腺瘤检出率在4个基因间相似,但MLH1/MSH2携带者总体AA检出率(14.5% vs 11.9%,P=.04)及10年累积AA检出率(21.6% vs 19.7%,P=.04)均高于MSH6/PMS2携带者;MSH6携带者AA检出率居中。多因素分析显示AA(OR 2.12,95%CI 1.08-4.17,P=.03)和重复AA检出(OR 4.62,95%CI 1.70-12.57,P<.01)是结肠镜检查后结直肠癌(PCCRC)的独立危险因素。
要点
- MLH1/MSH2携带者总体AA检出率14.5%,高于MSH6/PMS2携带者的11.9%(P=.04)。
- MLH1/MSH2携带者10年累积AA检出率21.6%,高于MSH6/PMS2携带者的19.7%(P=.04)。
- AA(OR 2.12)和重复AA检出(OR 4.62)是PCCRC的独立危险因素。
核心结论
- MLH1/MSH2致病性变异携带者较MSH6/PMS2突变携带者发生AA的风险更高,MSH6携带者呈现中间风险特征。
- AA是PCCRC的独立危险因素。
- 作者认为,伴有AA的林奇综合征患者应被识别为高风险人群并接受强化的结肠镜监测。
研究设计与样本
- 多中心研究,纳入1072例无结直肠癌史的林奇综合征携带者,接受监测性结肠镜检查。
- 按基因评估腺瘤和进展期腺瘤(AA)检出率,主要结局为比较MLH1/MSH2与MSH6/PMS2致病性变异携带者(无结直肠癌史)的腺瘤检出率。
- 亚组分析评估MSH6携带者相对于MLH1/MSH2和PMS2携带者的中间风险特征。
- 比较总体腺瘤检出率、腺瘤负荷、首次腺瘤发生年龄和10年累积检出率,并识别AA和PCCRC的危险因素。
- 进行多重检验和多因素分析。
主要发现
- 4个基因间的腺瘤检出率相似。
- MLH1/MSH2携带者总体AA检出率14.5%,高于MSH6/PMS2携带者的11.9%(P=.04)。
- MLH1/MSH2携带者10年累积AA检出率21.6%,高于MSH6/PMS2携带者的19.7%(P=.04)。
- 亚组分析显示MSH6携带者的AA检出率处于MLH1/MSH2携带者与PMS2携带者之间。
- 多因素分析显示AA(OR 2.12,95%CI 1.08-4.17,P=.03)和重复AA检出(OR 4.62,95%CI 1.70-12.57,P<.01)是PCCRC的独立危险因素。
临床怎么用
- 作者认为,伴有AA的林奇综合征患者应被识别为高风险人群并接受强化的结肠镜监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Colonoscopy is expected to reduce colorectal cancer (CRC) incidence in Lynch syndrome (LS) by detecting and removing adenomas. The existence of gene-specific differences in adenoma detection has been proposed yet remains insufficiently explored. This study aims to elucidate gene-specific adenoma detection rates and their association with post-colonoscopy CRC (PCCRC), which stands as an important issue in LS surveillance. METHODS: In this multicenter study, we analyzed 1072 LS carriers without prior CRC undergoing surveillance colonoscopy, evaluating adenoma and advanced adenoma (AA) detection rates by gene. The primary outcome was to compare adenoma detection rates in individuals without prior CRC carrying pathogenic variants in MLH1/MSH2 vs MSH6/PMS2. Subgroup analysis was performed to assess the intermediate risk profile in MSH6 carriers relative to MLH1/MSH2 and PMS2 carriers. We compared overall adenoma detection rates, adenoma burden, age at first adenoma occurrence, and 10-year cumulative detection rates. Risk factors for AA and PCCRC were also identified. Multiple testing and multivariate analyses were performed. RESULTS: The adenoma detection rates were similar across the 4 genes. However, MLH1/MSH2 carriers had a higher overall AA detection rate compared with MSH6/PMS2 carriers (14.5% vs 11.9%; P = .04) and showed higher cumulative AA detection rates over 10 years (21.6% vs 19.7%; P = .04). Subgroup analysis indicated that MSH6 carriers had an intermediate AA detection rate positioned between MLH1/MSH2 carriers and PMS2 carriers. Multivariate analysis indicated that AAs (odds ratio, 2.12; 95% confidence interval, 1.08-4.17; P=.03) and repeated AA detection (odds ratio, 4.62; 95% confidence interval, 1.70-12.57; P < .01) were independent risk factors for PCCRC. CONCLUSIONS: Carriers of MLH1/MSH2 pathogenic variants are at a higher risk of developing AAs compared with those with MSH6/PMS2 mutations, with MSH6 carriers exhibiting an intermediate risk profile. AAs are an independent risk factor for PCCRC. LS patients with AAs should be identified as high risk and undergo enhanced colonoscopy surveillance.
引用
- Sánchez A, Castillo-Iturra J, Roos VH, et al. Gene-Specific Detection Rate of Adenomas and Advanced Adenomas in Lynch Syndrome. Gastroenterology. 2025. PMID: 40315961. doi:10.1053/j.gastro.2025.03.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。